Pemazyre

Chemical Namepemigatinib
Dosage FormTablets (oral; 4.5 mg, 9 mg, 13.5 mg)
Drug ClassKinase inhibitors
SystemDigestive
CompanyIncyte Corporation
Approval Year2020

Indication

  • Indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pemazyre (pemigatinib) Prescribing Information.2020Incyte Corporation, Wilmington, DE